| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Cardiovascular Research Institute (P.Z., J.G., J.L., J.S.), Department of Cell Biology and Molecular Medicine, University of Medicine & Dentistry of New Jersey, New Jersey Medical School, Newark; and Oncology Research Institute (E.H., X.Y., T.W.), Greenville, SC.
Correspondence to Junichi Sadoshima, MD, PhD, Cardiovascular Research Institute, UMDNJ, New Jersey Medical School, 185 South Orange Ave, MSB G609, Newark, NJ 07103. E-mail sadoshju{at}umdnj.edu
We have shown previously that tyrosine 319 in a conserved YIPP motif in the C terminus of angiotensin II (Ang II) type 1 receptors (AT1Rs) is essential for transactivation of epidermal growth factor receptor (EGFR) in vitro. We hypothesized that the signaling mechanism mediated through the specific amino acid sequence in the G proteincoupled receptor plays an important role in mediating cardiac hypertrophy in vivo. Transgenic mice with cardiac-specific overexpression of wild-type AT1R (Tg-WT) and an AT1R with a mutation in the YIPP motif (Tg-Y319F) were studied. Tg-Y319F mice developed no significant cardiac hypertrophy, in contrast to the significant development of hypertrophy in Tg-WT mice. Expression of fetal-type genes, such as atrial natriuretic factor, was also significantly lower in Tg-Y319F than in Tg-WT mice. Infusion of Ang II caused an enhancement of hypertrophy in Tg-WT mice but failed to induce hypertrophy in Tg-Y319F mice. Left ventricular myocardium in Tg-Y319F mice developed significantly less apoptosis and fibrosis than that in Tg-WT mice. EGFR phosphorylation was significantly inhibited in Tg-Y319F mice, confirming that EGFR was not activated in Tg-Y319F mouse hearts. In contrast, activation/phosphorylation of protein kinase C, STAT3, extracellular signal-regulated kinase, and Akt and translocation of G
q/11 to the cytosolic fraction were maintained in Tg-Y319F hearts. Furthermore, a genetic cross between Tg-WT and transgenic mice with cardiac-specific overexpression of dominant negative EGFR mimicked the phenotype of Tg-Y319F mice. In conclusion, overexpression of AT1-Y319F in cardiac myocytes diminished EGFR transactivation and inhibited a pathological form of cardiac hypertrophy. The YIPP motif in the AT1R plays an important role in mediating cardiac hypertrophy in vivo.
Key Words: AT1 receptor YIPP motif transactivation EGFR hypertrophy
This article has been cited by other articles:
![]() |
R. J. Gelpi, S. Gao, P. Zhai, L. Yan, C. Hong, L. M. A. Danridge, H. Ge, Y. Maejima, M. Donato, M. Yokota, et al. Genetic inhibition of calcineurin induces diastolic dysfunction in mice with chronic pressure overload Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1814 - H1819. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Tilley, I.-M. Kim, P. A. Patel, J. D. Violin, and H. A. Rockman {beta}-Arrestin Mediates {beta}1-Adrenergic Receptor-Epidermal Growth Factor Receptor Interaction and Downstream Signaling J. Biol. Chem., July 24, 2009; 284(30): 20375 - 20386. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cai, F.-F. Yi, L. Yang, D.-F. Shen, Q. Yang, A. Li, A. K. Ghosh, Z.-Y. Bian, L. Yan, Q.-Z. Tang, et al. Targeted Expression of Receptor-Associated Late Transducer Inhibits Maladaptive Hypertrophy via Blocking Epidermal Growth Factor Receptor Signaling Hypertension, March 1, 2009; 53(3): 539 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F.X. Ainscough, M. J. Drinkhill, A. Sedo, N. A. Turner, D. A. Brooke, A. J. Balmforth, and S. G. Ball Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction Cardiovasc Res, February 15, 2009; 81(3): 592 - 600. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Rajagopalan, I. H. Zucker, J. A. Jones, M. Carlson, and Y. J. Ma Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H543 - H554. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Arcidiacono, T. Sato, D. Alvarez-Hernandez, J. Yang, M. Tokumoto, I. Gonzalez-Suarez, Y. Lu, Y. Tominaga, J. Cannata-Andia, E. Slatopolsky, et al. EGFR Activation Increases Parathyroid Hyperplasia and Calcitriol Resistance in Kidney Disease J. Am. Soc. Nephrol., February 1, 2008; 19(2): 310 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Frank, C. Kuhn, B. Brors, C. Hanselmann, M. Ludde, H. A. Katus, and N. Frey Gene Expression Pattern in Biomechanically Stretched Cardiomyocytes: Evidence for a Stretch-Specific Gene Program Hypertension, February 1, 2008; 51(2): 309 - 318. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mogi, M. Iwai, and M. Horiuchi Emerging Concepts of Regulation of Angiotensin II Receptors: New Players and Targets for Traditional Receptors Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2532 - 2539. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Zhai, S. Gao, E. Holle, X. Yu, A. Yatani, T. Wagner, and J. Sadoshima Glycogen Synthase Kinase-3{alpha} Reduces Cardiac Growth and Pressure Overload-induced Cardiac Hypertrophy by Inhibition of Extracellular Signal-regulated Kinases J. Biol. Chem., November 9, 2007; 282(45): 33181 - 33191. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Reudelhuber, K. E. Bernstein, and P. Delafontaine Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?: Time for Another Look Hypertension, June 1, 2007; 49(6): 1196 - 1201. [Full Text] [PDF] |
||||
![]() |
M. C. Schaub and M. A. Hefti The PGE2-Stat3 connection in cardiac hypertrophy Cardiovasc Res, January 1, 2007; 73(1): 3 - 5. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |